Compugen (CGEN) Q3 2026 earnings review
Compugen gains a 2027 partner catalyst, while its prepayments shrink
Compugen locked in the timeline for its own cancer trial while partner AstraZeneca brought a major late-stage readout closer. Chief executive Eran Ophir confirmed that the ovarian cancer trial of COM701 finished enrolling at 62 patients for a readout in early 2027, and AstraZeneca now expects late-stage biliary cancer results in the second half of 2027. Third-quarter revenue doubled to $3.8 million, above what the company's own recognition plan pointed to by our math, as it worked through Gilead's past upfront payment faster.
| Revenue (from Gilead prepayment) | $3.8M +102% from a year ago |
|---|---|
| Deferred revenue balance | $28.0M -27% from a year ago by our math |
| Cash and deposits | $117.5M funds operations into 2029 |
| AstraZeneca Phase 3 readout | H2 2027 previously expected after 2027 |
⚖️ Verdict: 🟢 Bullish
The story got better because Compugen now has two major clinical readouts set for 2027 instead of one. Finishing enrollment removes the delay risk on the ovarian cancer trial, and AstraZeneca's biliary cancer schedule pulls a late-stage readout into 2027 from 2028. One caution: the revenue beat came entirely from draining the Gilead prepayment liability faster, and the 62-patient ovarian trial remains small.
The question now is whether the 62-patient ovarian cancer trial can produce a clear win when results arrive in early 2027. Critics view the small sample and the company's focus on six-month tumour control as a lowered hurdle, while supporters see a realistic benchmark in a setting with no approved maintenance drugs. The first-quarter 2027 trial readout will settle it.
🐂 Bull Case
Partner AstraZeneca Will Report Phase 3 Results in 2027
Rilvegostomig is an experimental cancer antibody owned by drugmaker AstraZeneca that uses a component discovered by Compugen. The Israeli biotech can earn up to $195 million in future regulatory and commercial payments plus sales royalties from the partnership. Chief executive Eran Ophir highlighted "Phase 3 high-level trial results from ARTEMIDE-Biliary01 anticipated in the second half of 2027" for 760 biliary tract cancer patients.
That timeline pulls a major catalyst into next year, because management previously indicated that AstraZeneca's late-stage readouts would arrive after 2027. Furthermore, AstraZeneca is testing the drug across 12 late-stage trials and reported encouraging survival data in lung cancer in September. Positive biliary cancer results next year would move Compugen closer to regulatory payments without costing it any research cash.
What to watch: AstraZeneca's late-stage biliary cancer readout in the second half of 2027. A positive result would set up a regulatory filing, which triggers an extra $25 million payment to Compugen upon regulatory acceptance.
Ovarian Cancer Trial Finishes Enrolling With 62 Patients
COM701 is Compugen's wholly owned antibody for patients with relapsed ovarian cancer whose tumours responded to platinum chemotherapy. For several quarters, management declined to share exact patient counts while assuring investors that the study remained on schedule. This quarter, Ophir said "MAIA-ovarian is now fully enrolled, and we remain on track to report results by the end of the first quarter of 2027".
The company disclosed that the trial enrolled 62 patients, assigning two patients to the drug for every one on a placebo. Finishing enrollment removes the risk of further recruitment delays, which had already pushed this readout back once last year. Giving the exact patient count also finally lets investors judge the statistical size of the study.
What to watch: the ovarian cancer trial results by the end of the first quarter of 2027. Clear separation between the drug and placebo groups would justify advancing COM701 into a larger trial.
Slower Cash Burn Keeps the Company Funded Into 2029
Compugen funds its drug trials from a cash pile it built by selling future royalty rights to AstraZeneca late last year. At the end of September, cash, bank deposits and marketable securities stood at $117.5 million. By our math, the company burned $7.8 million of cash in the third quarter, down from $9.6 million in the second quarter and $10.7 million in the first.
Slower cash spending and $1.1 million in net interest income kept the balance sheet healthy without selling new shares. Because the company has no debt and kept operating expenses steady at $8.3 million, its cash easily covers both the ovarian cancer readout and AstraZeneca's biliary cancer readout next year.
What to watch: quarterly cash burn in the fourth quarter. Staying near $8 million per quarter would confirm that current clinical work requires no share sales before 2029.
🐻 Bear Case
Small Ovarian Trial Carries a Lower Bar for Success
MAIA-ovarian is Compugen's only wholly owned clinical trial and its main near-term catalyst. Over the past year, management lowered its estimate for how long placebo patients stay healthy from six months to four months. In this release, the company said it will evaluate "the magnitude and durability of separation between the COM701 and placebo arms and the proportion of patients remaining progression-free at six months".
With 62 total patients split two-to-one, only about 41 patients received COM701 and about 21 received a placebo, by our math. That sample is small, and leaning on overall data trends rather than a strict statistical hurdle makes an ambiguous result more likely. If the readout is muddled, Compugen has no other internal clinical trial ready to carry the story.
What to watch: the exact median time before tumours grow in both groups when results arrive in early 2027. A placebo group that lasts longer than four months without a three-month edge for COM701 would weaken the case for a larger trial.
Revenue Doubled by Draining the Gilead Prepayment Faster
Compugen reported $3.8 million in third-quarter revenue, double the $1.9 million it recorded a year ago. The company noted that revenue reflects "recognition of portions of both the upfront payment and the investigational new drug milestone payment under the license agreement with Gilead". That agreement covers GS-0321, an experimental antibody in early clinical testing that blocks a protein called IL-18 binding protein.
- Third-quarter revenue: $3.8 million, up 102% from a year ago
- Total deferred revenue: $28.0 million, down 26.7% from a year ago by our math
- Quarterly deferred revenue drop: $3.8 million, matching reported revenue
- Gross margin: 37.2%, up 24.4 percentage points as trial supply costs fell to 62.8% of revenue
While the top line beat the $2.9 million quarterly average implied by last quarter's annual recognition outlook by our math, no new cash arrived. Every dollar of revenue came out of the deferred revenue liability on the balance sheet, which runs dry by 2029 unless a partner pays a new milestone.
What to watch: total deferred revenue on the fourth-quarter balance sheet. Another drop without a new partner payment will confirm that revenue is simply an accounting drawdown of past cash.
Risks this quarter didn't answer
Three standing concerns about partner dependence, future share sales, and royalty terms received no new disclosures in the third-quarter release.
- Gilead trial readout date: Compugen is running the early-stage trial for GS-0321, but neither company has given a date for clinical data or the next payment trigger.
- Future share dilution: the company still has $100 million of unused capacity on its share-sale facility, which it would likely tap to fund a larger ovarian cancer trial if early data succeed.
- Reduced AstraZeneca royalty share: Compugen already sold a portion of its future rilvegostomig royalties for $65 million last December, and it still has not disclosed the exact percentage it gave up.
👓 Other Themes
UnigenX Expands AI Target Discovery Into T-Cell Engagers
Unigen is Compugen's artificial-intelligence software platform for finding new cancer drug targets. In October, the company introduced UnigenX, an upgrade that Ophir said "expands our discovery capabilities into novel tumor-associated antigens" for treatments like T-cell engagers, which link immune cells directly to tumours. That addresses the lack of visibility into early research, though any discovered targets remain years away from human trials.
💲 Other KPIs
Research and development spending fell 7.4% from the second quarter to $5.8 million, and rose 0.7% from a year ago. Because revenue doubled on faster accounting recognition, research costs dropped by 153.8 percentage points as a share of revenue by our math, helping narrow the operating loss.
The weighted average share count rose 1.3% from a year ago and 0.1% from the second quarter. After selling shares early last year, the biotech stopped tapping its share-sale program once it received $65 million from AstraZeneca in December 2025.
Net loss narrowed by 16.9% from $7.0 million a year ago, or to $0.06 per share from $0.07. Higher accounting revenue from the Gilead prepayment and $1.1 million of net financial income reduced the quarterly loss.
🔮 Guidance
Unchanged. Compugen still plans to report results from its ovarian cancer maintenance trial by the end of the first quarter of 2027. Completing enrollment at 62 patients this quarter removes the main operational hurdle to meeting this date, which management has held for four straight quarters after delaying it once in 2025.
Moved earlier. Partner AstraZeneca now expects high-level results from its 760-patient biliary tract cancer study in the second half of 2027. On last quarter's call, Compugen management had indicated that AstraZeneca's late-stage readouts would arrive after 2027, making this an earlier timeline for a major partner catalyst.
Unchanged. The Israeli biotech still expects its $117.5 million in cash and deposits to fund operations into 2029 without counting any new milestone payments. By our math, last quarter's annual recognition outlook leaves $7.8 million of Gilead deferred revenue to be booked over the next three quarters, which brings in no new cash.
❓ Key Questions
How many cancer progression events trigger the ovarian trial readout?
Management disclosed that 62 patients enrolled in MAIA-ovarian, but has not stated how many tumour progression events must occur before it unblinds the data in the first quarter of 2027.
How does the six-month benchmark compare to the old statistical bar?
Compugen shifted its focus to the share of patients staying progression-free at six months and overall data trends. Investors need to know how that maps to its earlier goal of a three-month improvement over placebo.
Why did Gilead deferred revenue recognition speed up this quarter?
Third-quarter revenue of $3.8 million beat the $2.9 million quarterly pace implied by last quarter's 12-month recognition outlook. Management did not explain whether extra patient cohorts in the Phase 1 trial drove the faster drawdown.
What share of future rilvegostomig royalties did Compugen sell?
With AstraZeneca's first Phase 3 readout now set for the second half of 2027, investors need the exact royalty percentage Compugen retained after selling a portion for $65 million in December 2025.